OptiBiotix announced that it had signed three commercialisation deals for its weight loss ingredient SlimBiome, one of its two marketed functional food ingredients. These take the total number of commercial deals for SlimBiome to 20 and are an important step towards further expanding the product's geographical reach and hence sales. We expect revenues from SlimBiome to reach nearly £1m in FY2020E, which we believe is conservative, and >£11m by 2024E, driven by growing sales of existing deals and new deals. OPTI is also generating revenues from its cholesterol-lowering probiotic LP-LDL and we expect two further products, SweetBiotix (calorie-free fibre for sugar replacement) and LP-GOS (prebiotic that enhances the effect of LP-LDL) to start generating first sales in 2020E, yielding combined portfolio sales of >£40m in 2024E. We maintain our OUTPERFORM recommendation, based on our view that OPTI is at the beginning of a long-term revenue growth cycle.
06 Dec 2019
Three more deals for SlimBiome
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Three more deals for SlimBiome
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
06 Dec 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
OptiBiotix announced that it had signed three commercialisation deals for its weight loss ingredient SlimBiome, one of its two marketed functional food ingredients. These take the total number of commercial deals for SlimBiome to 20 and are an important step towards further expanding the product's geographical reach and hence sales. We expect revenues from SlimBiome to reach nearly £1m in FY2020E, which we believe is conservative, and >£11m by 2024E, driven by growing sales of existing deals and new deals. OPTI is also generating revenues from its cholesterol-lowering probiotic LP-LDL and we expect two further products, SweetBiotix (calorie-free fibre for sugar replacement) and LP-GOS (prebiotic that enhances the effect of LP-LDL) to start generating first sales in 2020E, yielding combined portfolio sales of >£40m in 2024E. We maintain our OUTPERFORM recommendation, based on our view that OPTI is at the beginning of a long-term revenue growth cycle.